Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Infertility in Females01:28

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of endometrial...
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptic pregnancy.

Case reports in women's health·2023
Same author

Corrigendum dans la 'Directive clinique n<sup>o</sup> 431 : Hémorragie post-partum et choc hémorragique' [Journal of Obstetrics and Gynaecology Canada 2022; 44(12): 1311-1329.E1].

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2023
Same author

Corrigendum to 'Guideline No. 431: Postpartum Hemorrhage and Hemorrhagic Shock' [Journal of Obstetrics and Gynaecology Canada 2022; 44(12): 1293-1310.E1].

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2023
Same author

Corrigendum dans la 'Directive clinique n<sup>o</sup> 431 : Hémorragie post-partum et choc hémorragique' [Journal of Obstetrics and Gynaecology Canada 44 (2022) p1311-1329.e1].

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2023
Same author

Corrigendum to 'Guideline No. 431: Postpartum Hemorrhage and Hemorrhagic Shock' [Journal of Obstetrics and Gynaecology Canada 44 (2022) p1293-1310.e1].

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2023
Same author

Guideline No. 431: Postpartum Hemorrhage and Hemorrhagic Shock.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2022

Related Experiment Video

Updated: Jun 23, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

Recurrent miscarriage.

Kirsten Duckitt1, Aysha Qureshi

  • 1John Radcliffe Hospital, Oxford, UK.

BMJ Clinical Evidence
|May 20, 2009
PubMed
Summary

This systematic review examines treatments for recurrent miscarriage, affecting 1-2% of women. Evidence on interventions like aspirin and heparin for unexplained or antiphospholipid syndrome-related recurrent pregnancy loss is presented.

Area of Science:

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Clinical Evidence Synthesis

Background:

  • Recurrent miscarriage affects 1-2% of women, often with unknown causes.
  • Successful subsequent pregnancy rates decrease with maternal age and miscarriage history.
  • Antiphospholipid syndrome is identified in 15% of recurrent miscarriage cases.

Purpose of the Study:

  • To evaluate the effectiveness and safety of treatments for unexplained recurrent miscarriage.
  • To assess interventions for recurrent miscarriage associated with antiphospholipid syndrome.

Main Methods:

  • Systematic review of 14 studies including systematic reviews, RCTs, and observational studies.
  • Searched major databases (Medline, Embase, Cochrane Library) up to April 2007.

More Related Videos

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis
07:46

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis

Published on: October 13, 2023

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
04:08

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes

Published on: June 27, 2025

Related Experiment Videos

Last Updated: Jun 23, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis
07:46

Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis

Published on: October 13, 2023

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
04:08

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes

Published on: June 27, 2025

  • Included harms alerts from regulatory agencies (FDA, MHRA).

    • Main Results:

    • Evaluated evidence quality using GRADE methodology.
    • Identified various interventions for recurrent miscarriage.
    • Included studies on aspirin, heparin, progesterone, and other treatments.

    Conclusions:

    • Presents information on the effectiveness and safety of multiple interventions.
    • Covers treatments such as low-dose aspirin, heparin plus low-dose aspirin, and progesterone.
    • Includes interventions like corticosteroids, immunoglobulin treatment, and lifestyle adaptations.